• Home
  • Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Author List
Dvorak CC, Waters E, Temple WC, Salinas GC, Chu J, Winestone LE, Higham CS, Kharbanda S, Shimano KA, Avagyan S, Pauerstein P, Huang JN, Brooks JT, Long-Boyle JR
Publication
Transplantation and Cellular Therapy
Publication ID (Profile URL)
https://researcherprofiles.org/profile/711784222
Publication Year
2025
PubMed ID
41365398
Publication Title
Dvorak CC, Waters E, Temple WC, Salinas GC, Chu J, Winestone LE, Higham CS, Kharbanda S, Shimano KA, Avagyan S, Pauerstein P, Huang JN, Brooks JT, Long-Boyle JR. Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2025 Dec 07.